ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 3.26 USD -0.91%
Market Cap: 403.8m USD

ADC Therapeutics SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ADC Therapeutics SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Revenue
$75.2m
CAGR 3-Years
-22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Revenue
CHf4.4m
CAGR 3-Years
4%
CAGR 5-Years
-22%
CAGR 10-Years
-24%
CRISPR Therapeutics AG
NASDAQ:CRSP
Revenue
$38.3m
CAGR 3-Years
40%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Revenue
CHf236.2m
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
18%
Idorsia Ltd
SIX:IDIA
Revenue
CHf232.5m
CAGR 3-Years
69%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Revenue
CHf118.4m
CAGR 3-Years
98%
CAGR 5-Years
109%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
367.2m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.54 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Revenue?
Revenue
75.2m USD

Based on the financial report for Sep 30, 2025, ADC Therapeutics SA's Revenue amounts to 75.2m USD.

What is ADC Therapeutics SA's Revenue growth rate?
Revenue CAGR 3Y
-22%

Over the last year, the Revenue growth was -39%. The average annual Revenue growth rates for ADC Therapeutics SA have been -22% over the past three years .

Back to Top